Dr. Katja Aschermann is an accomplished leader in the biopharmaceutical industry with over 20 years of experience in various senior positions. Katja is passionate about the development of Advanced Therapy Medicinal Products (ATMPs) in start-ups and small to medium-sized enterprises (SMEs).

Her extensive experience spans from transforming academic spin-offs into GMP companies to submitting regulatory dossiers to the European Medicines Agency (EMA). She is a member of the ECA ATMP-Interest Group Board and has participated in the development of the "National Strategy for Gene and Cell-Based Therapies," coordinated by the Berlin Institute of Health (BIH) at Charité on behalf of the Federal Ministry of Education and Research (BMBF).

Since November 2024, she is working as a freelance consultant to the life science branch.